drugset
drugset / Trial / NCT03009734

Evaluation of ATx201 as a Topical Antibiotic Agent

NCT03009734 ↗

Phase 1/2 Completed 73 enrolled UNION therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

AntibioTx is developping ATx201 as a topical product for treatment of skin infections, including infected atopic dermatitis.

Timeline

Start
2016-12
Primary completion
2018-03
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ATx201 Unknown 2 % Topical

Indications

bacterial infectious disease